Model of the iohexol (Omnipaque) molecule. Ironically, had it not been for Nycomed's US licensee, Sterling Winthrop, this phenomenally successful product might never have reached the market. Nycomed had encountered problems during development and wanted to drop iohexol. Sterling convinced Nycomed to persevere. Nycomed followed Sterling's advice, the problems were solved and in 1985, Sterling launched Omnipaque in the US market.